masthead-publications

Categories

Filter by Topics

ADCC Gene Alteration ALK Angiogenesis Anti-TNF Alpha Therapy Apoptosis Asthma Autocrine Signaling Autoimmune Disorder Biofluid Biology of neoplasia Biomarker Analysis Biomarker Validation Biomarkers Bladder Bladder Cancer Brain Breast Cancer CDKN2A mutation Cells Cerebrospinal Fluid Childhood Atopic Dermatitis Chronic Obstructive Pulmonary Disease Circulating miRNAs cMET Colorectal cancer Comparison study Core Needle Biopsy Custom mRNA Cytokines Developmental Immunotherapy Developmental Therapeutics Diabetes Differential Gene Expression Analysis DLBCL Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Efficacy EGFR Muatations EMT Encephalophy Epstein-Barr ERBB3 Esophageal Cancer Exosomes Extracellular Vesicles Fabry Disease Feasibility FFPE FGF Ligand Trap FGFR Fibrous Tumors Follicular lymphoma Gene Expression Profiling Gene Fusions Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors Head and Neck Cancer Heart HER2 Histone Deacetylase Inhibitors HLA-E HPV HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Path Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune Tolerance Immune-related Colitis Immuno-Oncology Immunotherapy Inflammation Juvenile Arthritis Kidney Liposarcoma Liquid Biopsy Liver Lung Lupus Lymph Node Metastasis Lymphoma Mechanism of Action Melanoma Mesothelioma MET Microenvironment miRNA Molecular Characterization Mouse mRNA custom mTOR pathway Multiple Myeloma Muscle Mutations MYC NAFLD Nash and Fibrosis Natural Killer Cells Neoantigens Neuroendocrine Tumor Neurologic non-Hodgkin Lymphoma Novel Therapeutic Targets NTRK1 Oesophageal Adenocarcinoma Oncology Oral Cancer Osteoclast Ovarian cancer Pancreas Paralysis Parkinson's Disease Pathogenesis Pathway Analysis PBMCs PCA Cell Lines PIK3CA mutation Placenta Plasma Platform Comparison Predictive Modeling Programmed cell death protein 1 Progression free-survival Prostate qNPA qPCR Radioimmunotherapy Rearrangements Response rate RET Reveal Rheumatoid Arthritis Risk Score ROS1 safety Sarcoma Serum Signaling Inhibitors Signatures Sinonasal Carcinoma SPECS Lung Consortium Squamous cell carcinoma Sub-typing Surveillance Survival Outcomes Survival plots Synovial Fluid Therapeutic Response Therapeutic targets TMB Toxicity TP53 mutation Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes Urothelial carcinoma VEGFR Xenograft Tissue

2020

Comparison of immunohistochemical and gene expression profiling based subtype identification of diffuse large B-cell lymphoma. Focus on extranodal lymphoma

Tiemann, A., et al. Comparison of immunohistochemical and gene expression profiling based subtype identification of diffuse large B-cell lymphoma. Focus on extranodal lymphoma. Poster and Abstract 263 presentedDeutsche Gesellschaft Fur Hamatologie Und Medizinische Onkologie.  at Virtual Annual Meeting 2020 OCT 9 - 11. 

View External Link

Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial

Menter, T., et al. Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial.  British Journal of Haematology; 2020 Jun. doi: 10.1111/bjh.16876

Download pdf 858KB

Prognostic Factors, Therapeutic Approaches, and Distinct Immunobiologic Features in Patients with Primary Mediastinal Large B-cell Lymphoma on Long-term Follow-up

Zhou H., et al. Prognostic Factors, Therapeutic Approaches, and Distinct Immunobiologic Features in Patients with Primary Mediastinal Large B-cell Lymphoma on Long-term Follow-up. Blood Cancer Journal (2020)10:49

Download pdf 1.0MB

2019

Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with baseline Metabolic Tumor volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial.

Richter, J., et al. Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial. Blood Cancer Journal 2019 Aug 19; 9(67).

Download pdf 757KB

The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong Invitro Anti-Lymphoma activity Both as Single Agents and in Combination

Tarantelli, C., et al. The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong Invitro Anti-Lymphoma activity Both as Single Agents and in Combination. Paper presented at: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi; 2019 Jun 18-22; Lugano, Switzerland.  Hematological Oncology VOL 37, Issue S2. https://doi.org/10.1002/hon.90_2629

View External Link

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models

Hicks, S. W., et al. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Hematologica. 2019 Feb 7; 104(8):1633-1639

Download pdf 1.5MB

Nivolumab for Relapsed/Refractory Diffuse Large B-cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

Ansell, S. M., et al. Nivolumab for Relapsed/Refractory Diffuse Large B-cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. Journal of Clinical Oncology. 2019 Jan 8:37(6):481-489

Download pdf 873KB

2018

Comparison of Immunohistochemistry Assay Results with Gene Expression Profiling Methods for Diffuse Large B-Cell Lymphoma Subtype Identification in Matched Patient Samples.

Schaffer, M., et al. Comparison of Immunohistochemistry Assay Results with Gene Expression Profiling Methods for Diffuse Large B-Cell Lymphoma Subtype Identification in Matched Patient Samples. J Mol Biomark Diagn 2018, 9:2 DOI: 10.4172/2155-9929.1000386

Download pdf 1.3MB

Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial

Richter, J.  et al. Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial. Poster Presented at: ASH Annual meeting session 626. 2018 Dec 3. San Diego, CA

Download pdf 1.1MB
View External Link

Page last updated October 26, 2020